Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Braxia Scientific Corp. News

    0,007 € 0,00% +0,00 €
    22:31:08 Uhr L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3CPBM
    ISIN: CA1057361026
    US-Symbol: BRAXF
    Typ: Aktie

    Braxia Scientific Corp. News

    29.11.22 - PR Newswire
    Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America
    Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America PR Newswire
    01.11.22 - PR Newswire
    Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
    Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders PR Newswire
    04.10.22 - PR Newswire
    KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers
    KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers PR Newswire
    21.09.22 - PR Newswire
    Braxia Scientific Announces Board Appointment
    Braxia Scientific Announces Board Appointment PR Newswire
    16.09.22 - PR Newswire
    Braxia Scientific Announces Court Approval of Class Action Settlement in Canada
    Braxia Scientific Announces Court Approval of Class Action Settlement in Canada PR Newswire
    12.09.22 - PR Newswire
    Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home
    Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home PR Newswire
    09.09.22 - PR Newswire
    Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
    Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 PR Newswire
    29.08.22 - PR Newswire
    Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients
    Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients PR Newswire
    03.08.22 - PR Newswire
    Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.
    Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the ...
    29.07.22 - PR Newswire
    Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
    Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results PR Newswire
    27.07.22 - PR Newswire
    Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth
    Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth PR Newswire
    24.06.22 - PR Newswire
    Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond
    Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and Beyond PR Newswire
    15.06.22 - PR Newswire
    Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders
    Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related ...
    02.06.22 - PR Newswire
    Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression
    Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-​Dose Clinical Trial of Psilocybin-​Assisted Therapy for Treatment Resistant Depression PR ...
    20.05.22 - PR Newswire
    Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
    Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-​Assisted Therapy for Depression in Ontario PR Newswire
    19.05.22 - PR Newswire
    Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022
    Braxia Scientific to Present at H.C. Wainwright Global Investment Conference, Miami from May 24-26, 2022 PR Newswire
    18.05.22 - PR Newswire
    Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of Psychiatry
    Braxia Scientific CEO to Speak at American Psychiatric Association Annual Meeting on Treatment Resistant Depression and Ketamine Guidelines Published in American Journal of ...
    13.04.22 - PR Newswire
    UPDATE - Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada
    UPDATE - Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada PR Newswire
    13.04.22 - PR Newswire
    Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada
    Braxia Scientific Reaches Agreements to Settle Class Actions in US and Canada PR Newswire
    01.04.22 - PR Newswire
    Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6
    Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6 PR ...

    Newssuche

    Videos

    newspaper
    09:30 Uhr +21,95%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »